MAP2K7 and adenomyosis: While perioperative treatment with the MEK/ERK inhibitor U0126 did not reduce the incidence of adenomyosis significantly, both treatments significantly decelerated the establishment of adenomyosis and the progression of EMT, FMT and fibrogenesis in adenomyotic lesions.